Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients

January 14, 2022 updated by: Stanford University
The purpose of this study is to assess the use of technology including remote vital sign monitoring in improving quality of patient care, decreasing hospital admissions and re-admissions, decreasing hospital length of stay and decreasing use of personal protective equipment.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Stanford, California, United States, 94305
        • Stanford University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hospitalized patient with COVID 19 or outpatient under investigation for or diagnosed with COVID 19
  • Clinically stable (on 4L O2 or less, non ICU)
  • Demonstrates ability to be trained in use of digital stethoscope technology

Exclusion Criteria:

  • Pregnancy
  • Delirium

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: COVID-19 Patients
Patients that are admitted to the hospital with COVID 19.
Behavioral: Doctorgram Patient Kit
Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient provider experience survey score
Time Frame: Once after completion of device use (up to 15 minutes to complete the survey)
Five questions related to satisfaction with experience using home pulse oximetry, each on a scale of 1 (poor) to 5 (excellent) summed and averaged for an overall range of 1 to 5 (higher scores = better experience).
Once after completion of device use (up to 15 minutes to complete the survey)
Provider experience survey score
Time Frame: Once after completion of device use (up to 15 minutes to complete the survey)
Four questions related to satisfaction with experience using home pulse oximetry, each on a scale of 1 (poor) to 5 (excellent) summed and averaged for an overall range of 1 to 4 (higher scores = better experience).
Once after completion of device use (up to 15 minutes to complete the survey)
Use of personal protective improvement
Time Frame: 6 months
Level of personal protective improvement in an in-patient setting.
6 months
Number of in-patient encounters with COVID patients as a measure of provider exposure to high risk illness
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stanford University

Investigators

  • Principal Investigator: Ritu Parikh, MD, Stanford University
  • Principal Investigator: Julieta M Gabiola, MD, Stanford University
  • Principal Investigator: Nicholas Scoulios, MD, Stanford University
  • Principal Investigator: Lisa Shieh, MD, Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 1, 2022

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

July 17, 2020

First Submitted That Met QC Criteria

July 17, 2020

First Posted (Actual)

July 21, 2020

Study Record Updates

Last Update Posted (Actual)

January 31, 2022

Last Update Submitted That Met QC Criteria

January 14, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 56472

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Doctorgram Patient Kit

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe